Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-adjuvanted Vaccine Coadministered With Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine and/or Meningococcal Conjugate Vaccine to Healthy Girls 11 to 18 Years of Age

201134 citationsJournal Article

Authors

Cosette M. Wheeler · University of Louisville

Bryan M. Harvey · Q-Biologicals (Belgium)

Michael E. Pichichero · Legacy International

Michael Simon

Stephen P. Combs

Mark M. Blatter

Gary S. Marshall · University of Louisville

Grégory Catteau · Q-Biologicals (Belgium)

Abstract

Concomitant administration of HPV-16/18 AS04-adjuvanted vaccine with Tdap and/or MCV4 in different regimens did not interfere with the immune response to any of the vaccines and had an acceptable safety profile.

Topics & Keywords

Cervical Cancer and HPV Research Hepatitis B Virus Studies Immunotherapy and Immune Responses

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Pediatric Infectious Disease Journal

Volume 30, Issue 12, pp. e225-e234

DOI: 10.1097/inf.0b013e31822d28df

Field-Weighted Citation Impact: 3.19